Jennifer Sharpe Potter

Summary

Affiliation: University of Texas Health Science Center
Country: USA

Publications

  1. ncbi Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: secondary analyses from the Clinical Trials Network
    Jennifer Sharpe Potter
    Division of Alcohol and Drug Abuse, Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    J Subst Abuse Treat 38:S80-6. 2010
  2. ncbi Site selection in community-based clinical trials for substance use disorders: strategies for effective site selection
    Jennifer Sharpe Potter
    Division of Alcohol and Drug Abuse, Department of Psychiatry, School of Medicine, University of Texas Health Science Center, San Antonio, 78232, USA
    Am J Drug Alcohol Abuse 37:400-7. 2011
  3. ncbi Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial
    Roger D Weiss
    Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA 02478, USA
    Arch Gen Psychiatry 68:1238-46. 2011
  4. ncbi Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial
    George E Woody
    Department of Psychiatry, Treatment Research Institute, University of Pennsylvania, 150 S Independence Mall W, Ste 600, Philadelphia, PA 19106, USA
    JAMA 300:2003-11. 2008
  5. ncbi Determining the primary endpoint for a stimulant abuse trial: lessons learned from STRIDE (CTN 0037)
    Madhukar H Trivedi
    Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 75390 9119, USA
    Am J Drug Alcohol Abuse 37:339-49. 2011
  6. ncbi Characteristics of first-time alcohol treatment seekers: the COMBINE Study
    Joseph S Locastro
    Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, and Veterans Affairs Boston Healthcare System, Boston, Massachusetts, USA
    J Stud Alcohol Drugs 69:885-95. 2008

Collaborators

Detail Information

Publications6

  1. ncbi Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: secondary analyses from the Clinical Trials Network
    Jennifer Sharpe Potter
    Division of Alcohol and Drug Abuse, Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    J Subst Abuse Treat 38:S80-6. 2010
    ..These findings lend further support for continued research on pain among patients with opioid dependence...
  2. ncbi Site selection in community-based clinical trials for substance use disorders: strategies for effective site selection
    Jennifer Sharpe Potter
    Division of Alcohol and Drug Abuse, Department of Psychiatry, School of Medicine, University of Texas Health Science Center, San Antonio, 78232, USA
    Am J Drug Alcohol Abuse 37:400-7. 2011
    ..Selecting high-quality sites to participate is critical to recruitment, retention, and overall trial performance when conducting multi-site, community-based clinical trials of treatments for substance use disorders...
  3. ncbi Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial
    Roger D Weiss
    Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA 02478, USA
    Arch Gen Psychiatry 68:1238-46. 2011
    ..No randomized trials have examined treatments for prescription opioid dependence, despite its increasing prevalence...
  4. ncbi Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial
    George E Woody
    Department of Psychiatry, Treatment Research Institute, University of Pennsylvania, 150 S Independence Mall W, Ste 600, Philadelphia, PA 19106, USA
    JAMA 300:2003-11. 2008
    ..The usual treatment for opioid-addicted youth is detoxification and counseling. Extended medication-assisted therapy may be more helpful...
  5. ncbi Determining the primary endpoint for a stimulant abuse trial: lessons learned from STRIDE (CTN 0037)
    Madhukar H Trivedi
    Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 75390 9119, USA
    Am J Drug Alcohol Abuse 37:339-49. 2011
    ..Abstinence is the most desirable treatment outcome although a wide variety of other endpoints have been used...
  6. ncbi Characteristics of first-time alcohol treatment seekers: the COMBINE Study
    Joseph S Locastro
    Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, and Veterans Affairs Boston Healthcare System, Boston, Massachusetts, USA
    J Stud Alcohol Drugs 69:885-95. 2008
    ....